The relationship of p53 accumulation and DNA ploidy and conventional clinicopathological prognostic variables in patients with ovarian carcinoma

Geburtshilfe und Frauenheilkunde

Volumn 65, Issue 8, 2005, Pages 778-785

  Osmanaǧaoǧlu, Mehmet A ^a   Kadioglu S ^a   Osmanagaoglu S ^a   Bozkaya, H ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

DNA ploidy; Ovarian cancer; p53; Prognostic factors

Indexed keywords

DNA; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; PLOIDY; PROGNOSIS; PROTEIN DETERMINATION; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME; TUMOR RECURRENCE;

EID: 24744457571     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865945     Document Type: Article

References (34)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26
2. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825
3. Harris CC. Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455
4. Geisler JP, Geisler HE, Wiemann MC, Givens SS, Jhou Z, Miller GA. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol 1997; 66: 435-438
5. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175-1179
6. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-69
7. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995; 76: 1201-1208
8. Herod J, Eliopoulos A, Warwick J, Niedobitek G, Young L, Kerr D. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-2184
9. Eltabbakkah GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer (Phila) 1997; 80: 892-898
10. Röhlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Loning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 Immunoreactivity. J Cancer Res Clin Oncol 1997; 123: 496-501
11. Werness BA, Freedman AN, Piver S, Romero-Gutierrez M, Petrow E. Prognostic significance of p53 and p21 immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 1999; 75: 413-418
12. Anttila MA, Ji H, Juhola MT, Saarikoski SV, Syrjänen KJ. The prognostic significance of p53 expression quantified by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 1999; 18: 42-51
13. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988; 61: 334-339
14. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988; 6: 282-290
15. Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M. Flow cytometric analysis of DNA content in human ovarian cancers. Br J Cancer 1989; 60: 45-50
16. Wils J, van Geuns H, Baak J. Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer. Cancer 1988; 61: 1920-1925
17. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263-264
18. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335
19. 6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer. Int J Cancer 1999; 84: 388-395
20. Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999; 81: 733-740
21. Reles AE, Gee C, Schellschmidt I, Schmider A, Unger M, Friedmann W et al. Prognostic Significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. Gynecol Oncol 1998; 71: 3-13
22. Friedlander ML, Russell P, Taylor IW, Hedley DW, Tattersall MH. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology 1984; 16: 301-306
23. Christov K, Vassilev N. Flow cytometric analysis of DNA and cell proliferation in ovarian tumours. Cancer 1988; 61: 121-125
24. Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003; 192: 227-235
25. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB. TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 2004; 90: 678-685
26. Skirnisdottir I, Sorbe B, Karlsson M, Seidal T. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma. Int J Oncol 2001; 19: 1295-1302
27. Zanetta GM, Keeney GL, Kimlinger TK, Katzmann JA, Podratz KC. Concordance of DNA ploidy pattern as measured by flow cytometry in primary, metastatic, and persistent ovarian carcinoma. Gynecol Oncol 1996; 60: 213-216
28. Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Baiocchi G, Di Stefano P et al. Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynecol Cancer 1993; 3: 271-278
29. Wagner TM, Adler A, Sevelda P, Assmann I, Knepfle CF, Czerwenka K et al. Prognostic significance of cell DNA content in early-stage ovarian cancer (FIGO stages I and II/A) by means of automatic image cytometry. Int J Cancer 1994; 56: 167-172
30. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 1993; 81: 643-650
31. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18: 3936-3945
32. Harlozinska A, Bar J, Montenarh M. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM 2 protein expression in ovarian carcinomas. Anticancer Res 2000; 20: 1049-1056
33. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol 1999; 18: 29-41
34. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-2997